Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Outlook Therapeutics, Inc.OTLK · Entity 608 | Chief Operations Officer | April 20, 2023 | April 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Outlook Therapeutics, Inc.
Report date April 20, 2023 · Filed April 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 653,058 |
Reported balance
After 2023-04-20 transaction · row 1
1 source rowRow 1 · 2023-04-20 · Sale · Disposed 520,000 · Balance 653,058 F1: These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2023 Filed Apr 21, 2023 21:05 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | SaleCommon Stock | 520,000 | $1.14 | $590,200.00 |
DisclosureSEC source: 0001209191-23-025294 · doc4.xml · nonDerivative · entry 1 Dagnon Terry · CIK 0001760510 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 653,058 F1 · shares: These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 17:41 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 192,143 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001209191-23-024881 · doc4.xml · derivative · entry 1 Dagnon Terry · CIK 0001760510 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,143 Underlying: Common Stock · 192,143 shares Expires 2033-04-17 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on April 17, 2024, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 17:08 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 10,000 | $1.05 | $10,500.00 |
DisclosureSEC source: 0001209191-22-038989 · doc4.xml · nonDerivative · entry 1 Dagnon Terry · CIK 0001760510 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,173,058 Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 18:46 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001209191-22-022672 · doc4.xml · derivative · entry 1 Dagnon Terry · CIK 0001760510 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-21 F1 · shares: Represents the number of shares that vested under a performance-based stock option grant based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based vesting conditions of the option, such shares were not reportable under Section 16 until vesting was determined, which occurred on March 31, 2022. The vested shares represents the first of three possible vesting events of the total number of shares subject to the option. The remaining shares subject to the option will vest only upon the satisfaction of additional performance vesting criteria. F2 · derivative.exercise_date: Fully vested and immediately exercisable. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 17:31 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001209191-21-071122 · doc4.xml · derivative · entry 1 Dagnon Terry · CIK 0001760510 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2031-12-21 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on December 21, 2022, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances. Read SEC document |
| December 06, 2021 Filed Dec 6, 2021 17:26 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 25,201 | $1.38 | $34,777.38 |
DisclosureSEC source: 0001209191-21-068135 · doc4.xml · nonDerivative · entry 1 Dagnon Terry · CIK 0001760510 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,163,058 Read SEC document |
| December 03, 2021 Filed Dec 3, 2021 16:32 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 10,000 | $1.42 | $14,200.00 |
DisclosureSEC source: 0001209191-21-067838 · doc4.xml · nonDerivative · entry 1 Dagnon Terry · CIK 0001760510 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,137,857 Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 20:51 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | SaleCommon Stock | 15,900 | $2.09 | $33,199.20 |
DisclosureSEC source: 0001209191-21-014542 · doc4.xml · nonDerivative · entry 1 Dagnon Terry · CIK 0001760510 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,127,857 F1 · shares: These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 25% of the shares as provided in that certain Consulting Agreement dated January 27, 2020. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:13 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | SaleCommon Stock | 63,700 | $2.55 | $162,435.00 |
DisclosureSEC source: 0001209191-21-011611 · doc4.xml · nonDerivative · entry 1 Dagnon Terry · CIK 0001760510 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,143,757 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 - $2.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 25% of the shares as provided in that certain Consulting Agreement dated January 27, 2020. Read SEC document |
| March 19, 2020 Filed Apr 21, 2020 18:40 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantCommon Stock | 1,207,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025304 · doc4.xml · nonDerivative · entry 1 Dagnon Terry · CIK 0001760510 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,207,457 F1 · shares: These shares were issued to the Reporting Person pursuant to the terms of that certain Consulting Agreement dated January 27, 2020, and are subject to repurchase by the Issuer as provided therein. F1 · price: These shares were issued to the Reporting Person pursuant to the terms of that certain Consulting Agreement dated January 27, 2020, and are subject to repurchase by the Issuer as provided therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.